Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
886.6 INR | -1.14% | +1.12% | +36.55% |
Apr. 30 | Strides Pharma Science Limited Approves Appointment of Ameet P Hariani as Independent Director | CI |
Apr. 09 | Strides Pharma Science Gets US FDA Nod for Fluoxetine Tabs | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+36.55% | 977M | B | ||
+19.98% | 43.48B | B- | ||
+20.67% | 22.65B | B+ | ||
+14.56% | 14.73B | - | ||
+14.32% | 13.79B | B+ | ||
+44.72% | 12.04B | B | ||
-8.37% | 7.08B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+11.90% | 5.47B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- STAR Stock
- Ratings Strides Pharma Science Limited